Intercept Pharmaceuticals Reports Additional Details About FLINT Trial Provided By NIDDK

Published: Jan 13, 2014

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

NEW YORK, Jan. 12, 2014 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (Intercept) today provided additional information regarding the FLINT clinical trial of obeticholic acid (OCA) in nonalcoholic steatohepatitis (NASH), based on a written statement distributed after market close on January 10, 2014 by the National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK), a part of the National Institutes of Health.

Help employers find you! Check out all the jobs and post your resume.

Back to news